EUCTR2014-005350-19-ES进行中（未招募）1 期
A phase I/II study of nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with previously untreated, metastatic pancreatic adenocarcinoma - SEQUENCE
Grupo de Tratamiento de los Tumores Digestivos (TTD)0 个研究点目标入组 168 人开始时间: 2015年5月8日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically and/or cytologically confirmed pancreatic adenocarcinoma
- •- Stage IV disease (metastatic pancreatic cancer).
- •- No prior systemic therapy for their diagnosis (except in adjuvant setting with or without radiotherapy during previous six months.
- •- ECOG performance status of 0-1
- •- At least 18 years of age
- •- RECIST versión 1.1. defined measurable disease
- •- Female patients must be either surgically sterile or postmenopausal, or if of childbearing potential must have
- •a negative pregnancy test (serum or urine) prior to
- •enrollment and agree to use effective barrier contraception during the period of therapy. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator.
- •- Adequate bone marrow function:
- •ANC = 1500/uL
- •Platelet count =100,000/uL
- •Hemoglobin = 9.0 g/dL
- •- Adequate hepatic function:
- •Total bilirubin = 1.5 X ULN or until 2mg/dL
- •AST (SGOT) = 2.5 X ULN = 5 X ULN if liver metastases
- •ALT (SGPT) = 2.5 X ULN = 5 X ULN if liver metastases
- •Adequate renal function as determined by either:
- •- Calculated or measured creatinine clearance = 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used)
- •- Ability to understand the nature of this study protocol and give written informed consent.
- •- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study.
- •- Presence of central nervous system or brain metastases.
- •- Life expectancy < 12 weeks.
- •- Pregnancy (positive pregnancy test) or lactation.
- •- Pre-existing sensory neuropathy > grade 1.
- •- Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
- •- Major surgery within 4 weeks of the start of study treatment, without complete recovery.
- •- Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years
研究者
相似试验
已完成
不适用
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
招募中
2 期
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
已完成
2 期
Randomized phase II study of nab-Paclitaxel (nab-PTX) plus Carboplatin(CBDCA) followed by maintenance nab-PTX or TS-1 plus CBDCA followed by maintenance TS-1 as first-line treatment in patients with stage IIIB/IV squamous cell carcinoma of the lung.squamous cell carcinoma of the lungJPRN-UMIN000012903Internationanl University of Health and Welfare, Respiratory Disease center58
已完成
1 期
Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaNCT02504333Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)168
已完成
2 期
Phase II pilot study of nab-paclitaxel in patients with metastatic or unresectable urothelial cancer previously treated with cisplatin-based chemotherapy.urothelial cancerJPRN-UMIN000015260Department of Urology, Saitama Medical Center, Saitama Medical University5